CHICAGO — In this Healio Video Perspective from the AAO meeting, Rishi P. Singh, MD, discusses the results of the phase 3 TENAYA and LUCERNE trials investigating faricimab for the treatment of neovascular age-related macular degeneration.
“The trial was very interesting because it found an incredible durability of faricimab compared to aflibercept ... with almost 80% of patients achieving a Q12 or greater longer duration of dosing during the course of the study,” Singh said.